Skip to main content
. Author manuscript; available in PMC: 2014 May 13.
Published in final edited form as: Brain Res. 2013 Mar 19;1510:38–47. doi: 10.1016/j.brainres.2013.03.010

Figure 3.

Figure 3

Somatostatin does not protect dopamine terminals from METH toxicity. (A) Western blot analysis was used to measure striatal tyrosine hydroxylase (TH) protein levels and thus determine dopamine terminal viability. (B) Pretreatment with the SST analogue octreotide (OCT) failed to protect from METH-induced dopamine terminal degeneration. Mice (n=6) received intrastriatal infusions of aCSF (right striatum) or OCT (left striatum); followed 15 minutes later by an injection of METH (30 mg/kg, i.p.) or saline. Animals were sacrificed at 72 hours after METH treatment. (* p<0.05, **p<0.01 as compared to the aCSF group).